Cadrenal Therapeutics Faces Delisting Concerns
Ticker: CVKD · Form: 8-K · Filed: Sep 5, 2024 · CIK: 1937993
Sentiment: bearish
Topics: delisting, listing-rule, regulatory
Related Tickers: CADX
TL;DR
CADX might be delisted - big trouble ahead.
AI Summary
Cadrenal Therapeutics, Inc. filed an 8-K on September 5, 2024, to report a notice of delisting or failure to satisfy a continued listing rule. The company is incorporated in Delaware and its principal executive offices are located in Ponte Vedra, Florida.
Why It Matters
This filing indicates potential issues with Cadrenal Therapeutics' continued listing on an exchange, which could significantly impact its stock trading and investor confidence.
Risk Assessment
Risk Level: high — The filing explicitly states a notice of delisting or failure to satisfy a continued listing rule, which is a severe risk for the company and its shareholders.
Key Players & Entities
- Cadrenal Therapeutics, Inc. (company) — Registrant
- September 5, 2024 (date) — Date of Report
- Delaware (jurisdiction) — State of Incorporation
- Ponte Vedra, Florida (location) — Principal Executive Offices
FAQ
What specific listing rule or standard has Cadrenal Therapeutics failed to satisfy?
The filing does not specify the exact rule or standard that Cadrenal Therapeutics has failed to satisfy, only that a notice of delisting or failure to satisfy a continued listing rule or standard has been issued.
What is the date of the earliest event reported in this 8-K filing?
The date of the earliest event reported is September 5, 2024.
What is the Commission File Number for Cadrenal Therapeutics, Inc.?
The Commission File Number for Cadrenal Therapeutics, Inc. is 001-41596.
Where are Cadrenal Therapeutics, Inc.'s principal executive offices located?
Cadrenal Therapeutics, Inc.'s principal executive offices are located at 822 A1A North, Suite 306, Ponte Vedra, Florida 32082.
What is the IRS Employer Identification Number for Cadrenal Therapeutics, Inc.?
The IRS Employer Identification Number for Cadrenal Therapeutics, Inc. is 88-0860746.
Filing Stats: 494 words · 2 min read · ~2 pages · Grade level 12.4 · Accepted 2024-09-05 16:59:33
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share CVKD The Nasdaq Stock Mar
- $1.00 — the Company's common stock has been at $1.00 per share or greater. Accordingly, the
Filing Documents
- ea021370601-8k_cadrenal.htm (8-K) — 25KB
- 0001213900-24-076144.txt ( ) — 196KB
- cvkd-20240905.xsd (EX-101.SCH) — 3KB
- cvkd-20240905_lab.xml (EX-101.LAB) — 33KB
- cvkd-20240905_pre.xml (EX-101.PRE) — 22KB
- ea021370601-8k_cadrenal_htm.xml (XML) — 4KB
01 Notice
Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing On September 5, 2024, Cadrenal Therapeutics, Inc., a Delaware corporation (the "Company"), received a letter (the "Notification Letter") from The Nasdaq Stock Market ("Nasdaq") stating that for the last 10 consecutive business days, from August 20, 2024 through September 4, 2024, the closing bid price of the Company's common stock has been at $1.00 per share or greater. Accordingly, the Company has regained compliance with Listing Rule 5550(a)(2) and this matter is now closed.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits The following exhibits are furnished with this Current Report on Form 8-K: Exhibit Number Exhibit Description 104 Cover Page Interactive Data File (the cover page XBRL tags are embedded within in the inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: September 5, 2024 CADRENAL THERAPEUTICS, INC. By: /s/ Quang Pham Name: Quang Pham Title: Chairman and Chief Executive Officer